share_log

Guggenheim Downgrades RAPT Therapeutics to Neutral

Benzinga ·  May 10 18:29

Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment